Filing Flows

Filing Flows › Bristol Myers Squibb (BMY) › Q1 2026

Bristol Myers Squibb (BMY) Q1 2026 earnings results (first quarter 2026)

10-Q filed Apr 30, 2026

Bristol Myers Squibb (BMY) reported revenue of $11.5B for the first quarter 2026 (Q1 2026), +3% from a year earlier and -8% from the quarter before. Operating margin was 28.2%, net earnings $2.7B (23.3% of revenue).

Revenue$11.5B
Year over year+3%
Quarter over quarter-8%
Operating margin28.2%
Net earnings$2.7B

Bristol Myers Squibb, Q1 2026: revenue $11.5B (+3% year over year), operating margin 28.2%, net earnings $2.7B, operating cash flow $1.1B. The chart follows the revenue to costs, profit and cash.

Q1 2026AmountQ/QY/Y
Revenue$11.5B-8%+3%
Operating profit$3.2B+120%+9%
Net earnings$2.7B+147%+9%
Operating cash flow$1.1B-44%-44%
Free cash flow$757M-53%-55%

What changed

Revenue was $11.5B in Q1 2026, up 3% year over year and down 8% from the previous quarter. Growth Portfolio was the largest line at 54% of revenue. Growth Portfolio added $0.66B year over year (up 12%), 231% of the total change. Revlimid declined 63%.

Operating profit was $3.2B, a 28.2% margin (up 1.7 points year over year). Of the extra revenue versus Q1 2025, 93% reached operating profit, above the 27% margin then. Total costs grew 0% against revenue growth of 3%. The fastest-growing cost line was Research & development (+17%). Net earnings were $2.7B, up 9% year over year. The effective tax rate was 17.3%.

Operating cash flow was $1.1B (down 44% year over year), 41% of net earnings. Non-cash charges added back $0.59B of depreciation and amortization and $0.15B of share-based compensation. Working capital and other items used $2.3B. Capital expenditures of $0.35B left free cash flow of $0.76B.

Questions

What was Bristol Myers Squibb's revenue in the first quarter 2026?

Bristol Myers Squibb (BMY) reported revenue of $11.5B for the first quarter 2026 (Q1 2026), +3% from a year earlier and -8% from the quarter before.

Was Bristol Myers Squibb profitable in the first quarter 2026?

Operating profit was $3.2B (28.2% of revenue) and net earnings $2.7B.

Open the interactive Sankey →

Source: Bristol Myers Squibb 10-Q on SEC EDGAR.